Replimune Group (NASDAQ:REPL) Trading Up 8.2% – Time to Buy?

Replimune Group, Inc. (NASDAQ:REPL)’s share price traded up 8.2% on Friday . The stock traded as high as $13.03 and last traded at $12.99. 742,437 shares traded hands during trading, a decline of 29% from the average session volume of 1,046,092 shares. The stock had previously closed at $12.01.

Analysts Set New Price Targets

REPL has been the subject of several recent analyst reports. BMO Capital Markets raised their target price on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research note on Friday, November 22nd. JPMorgan Chase & Co. raised their price objective on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Roth Mkm initiated coverage on Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price on the stock. Jefferies Financial Group increased their price target on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Finally, Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $17.29.

Replimune Group Stock Up 4.0 %

The stock’s fifty day simple moving average is $12.25 and its 200-day simple moving average is $10.73. The stock has a market cap of $854.53 million, a P/E ratio of -4.10 and a beta of 1.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. As a group, research analysts forecast that Replimune Group, Inc. will post -2.91 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at $2,509,013.88. This represents a 4.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. This represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Barclays PLC grew its position in Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after acquiring an additional 98,791 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Replimune Group by 17.9% during the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after purchasing an additional 217,308 shares in the last quarter. State Street Corp grew its holdings in shares of Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after purchasing an additional 1,182,181 shares during the last quarter. Parkman Healthcare Partners LLC increased its stake in shares of Replimune Group by 45.5% in the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock valued at $8,371,000 after buying an additional 238,747 shares during the period. Finally, Arizona PSPRS Trust bought a new position in Replimune Group in the 3rd quarter valued at approximately $834,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.